Delayed SLND for Patients With Breast Cancer Undergoing Primary Systemic Treatment

Condition(s) studied

Investigational drug(s) / intervention(s)

SLND or TAD by the magnetic technique (SPIO): All patients will receive Radioisotope according to standard of care. They will also receive SPIO in a timeframe of clinical convenience, depending on whether primary response is planned by means of MRI. For patients that are ycN0, SLND or TAD will be performed. For those that convert from cN1 to ycN0, the index lymph node will be marked with a paramagnetic marker. Axillary surgery will be undertaken with the magnetic technique and each retrieved lymph node will be controlled for radiation. Upon the completion of the procedure, a background control will be performed with the radioactive signal as guide, to ensure standard of care best practice. Any palpable lymph nodes that are not sentinels with either tracer may be removed at surgeon discretion but will be reported seperately.

Study summary

The goal of this study was to assess the feasibility of SLND by superparamagnetic iron oxide nanoparticles (SPIO) in patients with early breast cancer planned for primary systemic therapy (PST) and whether this is affected by the timeframe of SPIO administration.

For this, patients with cN0/1 disease planned for PST received radioisotope as per routine on the day of surgery or the day before, and SPIO was injected in an extended timeframe, at any point from the day of surgery to before the induction of PST.

The main points to investigate are:

1. If the SPIO detection rate and concordance to the radiosotope are affected by time of SPIO injection
2. If the nodal yield and the accuracy of the procedure are affected

Eligibility

Primary outcome measure(s)

• Correlation between concordance (isotope and SPIO) and timepoint of SPIO administration to surgery — At surgery
  This endpoint is necessary in ensuring that prolonged SPIO administration does not result in the retrieval of "false" SLNs, in the case that SPIO migrates to higher nodal echelons. As the radioisotope is the current standard of care, the concordance of SPIO to the radioisotope and its correlation with time of SPIO adminstration is the appropriate surrogate endpoint.
• Detection rate — At surgery
  The successful retrieval of at least one SLN detected by each tracer (SPIO or radioisotope) separately.
• Concordance — At surgery
  The rate (patients with at least one SLN detected with both tracers/patients with at least one SLN detected with the radioisotope)

Trial sites (1)

More Uppsala University trials in Sweden

Other trials for the same condition